Natalizumab Treatment of Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study safety and efficacy of natalizumab treatment of primary
and secondary progressive multiple sclerosis.
This will be done by measuring the effect of treatment on inflammation in the CNS by means of
osteopontin levels in the cerebrospinal fluid (CSF). Safety measures further includes
physical and neurological examination,blood samples and MRI measures of disease activity.
Phase:
Phase 2
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Biogen Copenhagen University Hospital, Hvidovre Signifikans ApS University of Copenhagen